Cargando…
Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study
BACKGROUND: The safety of intraperitoneally administrated paclitaxel (op PTX) was demonstrated in the phase I trial of ip PTX combined with conventional systemic chemotherapy for colorectal cancer with peritoneal carcinomatosis. Moreover, the median survival time was 29.3 months, which was longer th...
Autores principales: | Murono, Koji, Yokoyama, Yuichiro, Nozawa, Hiroaki, Sasaki, Kazuhito, Emoto, Shigenobu, Matsuzaki, Hiroyuki, Kashiwabara, Kosuke, Ishigami, Hironori, Gohda, Yoshimasa, Yamaguchi, Hironori, Kitayama, Joji, Ishihara, Soichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282041/ https://www.ncbi.nlm.nih.gov/pubmed/37340243 http://dx.doi.org/10.1007/s00384-023-04434-5 |
Ejemplares similares
-
Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure
por: Kitayama, Joji, et al.
Publicado: (2014) -
A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report
por: Yamaguchi, Hironori, et al.
Publicado: (2016) -
A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3 years after intraperitoneal chemotherapy against peritoneal carcinomatosis
por: Okuno, Takayuki, et al.
Publicado: (2016) -
CD90(+) Mesothelial-Like Cells in Peritoneal Fluid Promote Peritoneal Metastasis by Forming a Tumor Permissive Microenvironment
por: Kitayama, Joji, et al.
Publicado: (2014) -
Analysis of pO(2) in Malignant Ascites of Patients with Peritoneal Dissemination of Gastric Cancer
por: Emoto, Shigenobu, et al.
Publicado: (2010)